- |||||||||| Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
Trial completion date, Trial termination: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - Jun 7, 2023 P2, N=69, Terminated, Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2023 --> Mar 2024 Trial completion date: Dec 2021 --> Jan 2023 | Recruiting --> Terminated; Futility analysis
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
Trial completion, Phase classification, Enrollment change: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - Mar 10, 2023 P3, N=9, Completed, Trial completion date: Dec 2021 --> Jan 2023 | Recruiting --> Terminated; Futility analysis Active, not recruiting --> Completed | Phase classification: P1/2 --> P3 | N=20 --> 9
- |||||||||| Journal: Opioids for pain. (Pubmed Central) - Dec 22, 2022
Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2023 No abstract available
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Review, Journal: Buprenorphine and its formulations: a comprehensive review. (Pubmed Central) - Aug 25, 2022 Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
Trial completion date: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - May 27, 2022 P1/2, N=20, Active, not recruiting, In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations. Trial completion date: Sep 2022 --> Dec 2022
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser
Preclinical, Journal: Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. (Pubmed Central) - Dec 16, 2021 Simbadol is a concentrated formulation of buprenorphine hydrochloride labeled for use in cats with recommended dosing frequency of every 24 h. We measured serum concentrations over time after a single injection of this product in C57BL/6NCrl mice and compared it to standard buprenorphine (Buprenex) and Buprenorphine SR-LAB...We conclude that Simbadol does not offer dosing advantages over the standard buprenorphine formulation when given at 1 mg/kg. Buprenorphine SR-LAB maintained a steady concentration of buprenorphine above 1ng/mL for at least 24 h, and as such is a superior choice for providing long-term analgesia.
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - May 24, 2021 P1/2, N=20, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
- |||||||||| Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
Enrollment open, Trial completion date, Trial primary completion date: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - May 10, 2021 P2, N=90, Recruiting, Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Feb 2022 Active, not recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
- |||||||||| Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
Enrollment change: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - Apr 19, 2020 P2, N=90, Active, not recruiting, Active, not recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Sep 2021 N=135 --> 90
- |||||||||| Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Buprenex (buprenorphine) / Reckitt Benckiser
Enrollment open: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (clinicaltrials.gov) - Mar 4, 2020 P2, N=135, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - Jan 22, 2020 P1/2, N=20, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Feb 2021
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - Sep 5, 2018 P1/2, N=20, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Feb 2021 Trial completion date: Mar 2018 --> Sep 2019 | Trial primary completion date: Mar 2018 --> Sep 2019
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser
Enrollment change: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - Nov 17, 2015 P1/2, N=20, Recruiting, Trial primary completion date: Dec 2015 --> Dec 2016 N=200 --> 20
- |||||||||| Buprenex (buprenorphine) / Reckitt Benckiser
Enrollment open, Trial initiation date: Buprenorphine Treatment for Opioid Dependence (clinicaltrials.gov) - Jul 15, 2015 P1/2, N=200, Recruiting, N=200 --> 20 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Mar 2015
|